EP
KALV

Essential Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Essential Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403 Hold
20
– – ﹤0.01% 2495
2025
Q4 		$323 Sell
20
-18
-47% -$238 ﹤0.01% 2321
2025
Q3 		$463 Hold
38
– – ﹤0.01% 2224
2025
Q2 		$430 Buy
+38
New +$465 ﹤0.01% 1744

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Essential Partners's KALV Position: Q1 2026 in Review

Essential Partners held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 20 shares worth $403. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

Essential Partners first reported a position in KALV in Q2 2025 and has held it in 4 quarters since. The position peaked at $463 in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Essential Partners held 20 shares of KalVista Pharmaceuticals worth $403 as of Q1 2026.
  • Essential Partners left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q1 2026, its #2495 holding.
  • Essential Partners first reported a position in KalVista Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Essential Partners's KalVista Pharmaceuticals position peaked at $463 in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.